Options Brief: Bears on the Attack as Shares of Affymax Sink

AFFY – Affymax, Inc. – Shares of the biopharmaceutical company plunged 68.7% to an intraday low of $7.20 today after data showed that non-dialysis patients taking Affymax’s anemia drug, Hematide, have a higher rate of heart attacks, chest pain, heart failure, arrhythmia, strokes and death than patients taking a similar drug made by Amgen Inc. The Hematide safety concerns inspired a downgrade of Affymax to ‘underperform’ from ‘outperform’ with a 12-month target share price of $7.00 by an analyst at RBC Capital this morning. Bearish options investors populating AFFY today initiated trades implying the price of the underlying stock will not recover in the next several months. Pessimistic players sold short roughly 2,800 calls at the July $10 strike to pocket an average premium of $0.37 apiece. Investors short the calls keep the full $0.37 premium received today as long as Affymax’s shares trade below $10.00 through July expiration. Call-selling spread to the October $10 strike where approximately 1,600 calls were shed for an average premium of $0.80 per contract. Investors keep the full $0.80 premium per contract if shares of the underlying stock fail to rally above $10.00 ahead of October expiration.

About Andrew Wilkinson 1023 Articles

Affiliation: Interactive Brokers

Andrew Wilkinson is the senior market analyst at Interactive Brokers Group, where he provides daily commentary and analysis on U.S. equity options trading throughout the trading day. Andrew provides webinars designed to explain option-related trading scenarios covering futures, fixed income, forex and equities.

Interactive Brokers: Interactive Brokers offers direct market access to around 80 electronic global markets from a single account. Successful traders and investors understand that superior technology and lower trading costs can result in greater returns. For 32 years we have been building direct access trading technology that delivers real advantages to professionals worldwide. With consolidated equity capital of US $4.4 billion, IB and its affiliates exceed 1,000,000 trades per day. In addition, our prudent and conservative risk policies make Interactive Brokers a safe haven for your money. Discover some of the reasons why IB, the largest independent US broker/dealer, is the professional traders' and investors' choice.

Visit: Interactive Brokers

Be the first to comment

Leave a Reply

Your email address will not be published.